Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -296.10% is 45% below its 3-year average of -203.99%, around the middle of its 3-year range (-592.23%–0.04%).
As of the fiscal period ended Tuesday, December 31, 2024. 97.97% below its 12-month average of -149.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2024 (2024-12-31): -296.10%.
RETURN ON EQUITY (ROE)
-296.10%
RETURN ON EQUITY (ROE) AVG TTM
-149.56%
RETURN ON EQUITY (ROE) AVG 3Y
-219.69%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-97.97%
CURRENT VS 3Y AVG
-34.78%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
-624.13%
vs the sector median at left
Moolec Science S.A.
Market Cap
$3.57M
Return on Equity (ROE)
-296.10%
TTM Avg
-149.56%
3Y Avg
-219.69%
5Y Avg
N/A
Market Cap
$3.51M
Return on Equity (ROE)
-591.60%
TTM Avg
-213.16%
3Y Avg
-150.57%
5Y Avg
-4.48%
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.79M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.84M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$3.29M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.29M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.23M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moolec Science S.A. (MLEC) | $3.57M | -296.10% | -149.56% | -219.69% | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.51M | -591.60% | -213.16% | -150.57% | -4.48% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| Eocene Ltd. (EOCN)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.84M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.29M | -282.13% | -313.25% | -153.55% | -153.55% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.29M | -133.43% | -203.84% | -174.81% | -140.61% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | -40.75% | -35.89% | -218.64% | -156.11% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.23M | N/A | -236.13% | -104.67% | -48.54% |
ROE
-296.1%
ROA
-8.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -296.10% |
| 2024-09-30 | -134.14% |
| 2024-06-30 | -107.28% |
| 2024-03-31 | -113.34% |
| 2023-12-31 | -96.96% |
| 2023-09-30 | -592.23% |
| 2023-06-30 | -511.28% |
| 2023-03-31 | -435.23% |
| 2022-12-31 | -430.74% |
| 2022-09-30 | -14.38% |
| 2022-06-30 | -122.50% |
| 2022-03-31 | -1.71% |
| 2021-12-31 | -0.07% |
| 2021-09-30 | 0.04% |
